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DEAR EDITOR, Hidradenitis suppurativa (HS) is a chronic, recur-
rent and debilitating skin disease of the hair follicle that is
accompanied by systemic inflammation. Treating HS is chal-
lenging, and therapeutic tools as diverse as topical and sys-
temic antibiotics, biologics, intralesional steroids, surgical
procedures or light and laser therapies are frequently needed.
The combination of oral clindamycin and rifampicin has been
suggested as a possible treatment regimen.
Five studies have evaluated the efficacy of this combination,
the majority of which reported the use of clindamycin
600 mg daily + rifampicin 600 mg daily with an average
length of 10 consecutive weeks.1–5 In three out of four stu-
dies, 10-week follow-up yielded complete remission in 32%
(32/116) of patients1–3; in another study, a 1-year follow-up
demonstrated sustained efficacy in only seven of 26 patients.5
Scheinfeld has discussed why rifampicin is a key drug in the
treatment of HS, pointing out its antibacterial and anti-inflam-
matory effects, its activity on bacterial biofilms, its effect
against granulomas and its immunomodulatory properties on
neutrophils.6
Rifampicin and the related rifamycins are the cornerstone of
the therapy for active tuberculosis (TB). Its use for other enti-
ties besides mycobacterial infections can hamper the future of
TB control and elimination, either by the emergence of resis-
tant strains or by the development of hypersensitivity reactions
that may contraindicate a future use of the drug. Spontaneous
mutations of Mycobacterium tuberculosis can cause decreased sus-
ceptibility to rifamycins, and antibiotic pressure from
monotherapy can result in the selection of these mutants and
the emergence of acquired drug resistance.7
During therapy of active TB disease, the emergence of rifa-
mycin resistance occurs only if one accidentally treats it with
a single drug without the coverage of the other antituberculo-
sis drugs.7 By prescribing the combination of clindamycin and
rifampicin, dermatologists are actually using rifampicin alone
as far as TB is concerned. This happens because clindamycin
has no tuberculostatic properties and patients with HS are not
routinely screened for TB before starting clindamycin–ri-
fampicin. Kayigire et al. recently published a study that rein-
forced the importance of this problem.8 Fourteen newly
diagnosed patients with TB were treated with rifampicin for
only 14 days and bacterial loads were determined, including
mutation frequencies. Using a statistical model to estimate the
rate of spontaneous mutations conferring resistance to rifampi-
cin in these patients, the authors concluded that 1% of the
remaining viable mycobacteria could already be resistant after
30 days of monotherapy.8
One could wonder whether combining two tuberculostatic
drugs to treat HS could minimize this issue. Moxifloxacin is a
second-line agent to treat TB. A retrospective case series study
evaluated the efficacy and safety of rifampicin + moxifloxacin
+ metronidazole for the treatment of HS in 28 patients;
despite the study’s methodological heterogeneity, it was
clearly shown that frequent (gastrointestinal disorders) and
potentially serious (tendon rupture) side-effects should limit
the use of this combination.9 However, even if rifampicin and
moxifloxacin are used simultaneously and a concomitant TB
diagnosis is missed, this regimen would still not be appropri-
ate to treat TB.
Hypersensitive reactions are infrequent in immunocompe-
tent patients treated with daily tuberculostatic regimens. Nev-
ertheless, there are some risk factors associated with the
development of sensitization; prior treatment with rifampicin
and poor compliance with intermittent dosages are two of
them.10 Should a patient develop TB in the future, prior inter-
mittent treatments with rifampicin, like those used for HS,
will naturally increase this risk.
The potential of rifampicin to treat HS has been acknowl-
edged, but all the pros and cons of its use must be thought-
fully considered. One must critically review its ability to
induce remission, the ultimate goal when treating these
patients, and consider alternative drugs for the management of
a chronic condition like HS. If it is at all needed, we advocate
systematic screening for TB in all patients with HS prior to
commencing clindamycin–rifampicin or other antibiotic
schemes including rifampicin, particularly in areas with high
or intermediate incidence rates of TB or in populations with
known risk factors. If a latent or active disease is diagnosed, a
multidisciplinary approach involving a TB specialist is recom-
mended.
On the whole, the rifamycins have transformed the treat-
ment of tuberculosis over recent years, and protecting their
tuberculostatic activity is critically important.
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